Alzheimer Scotland propose new assessment process after latest Scottish Medicines Consortium rejection of donanemab
Alzheimer Scotland has proposed a new assessment process after the Scottish Medicines Consortium reviewed further evidence on donanemab and continued to reject its use by NHS Scotland.
Henry Simmonds, Alzheimer Scotland’s Chief Executive, says:
“This demonstrates the urgent need for change in the system used to assess dementia drugs if we have any hope of tackling this disease. We understand that the SMC has established assessment protocols and criteria, however we believe that moving from clinical trials into clinical practice based on the current process is not working.
We would like to see a new element to the assessment process and that would be the introduction of dedicated pilot sites. These can be used to further test new promising treatments in meaningful clinical practice before a decision on NHS provision is made.”
Read more from Alzheimer Scotland here: https://www.alzscot.org/smc-review-of-donanemab/
Read Dementia Community’s previous news items on donanemab here: https://journalofdementiacare.co.uk/?s=donanemab